Algert Global LLC Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Algert Global LLC grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 66.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,550 shares of the company's stock after buying an additional 15,386 shares during the quarter. Algert Global LLC owned approximately 0.06% of Vera Therapeutics worth $1,630,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Huntington National Bank purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth approximately $26,000. Summit Investment Advisors Inc. raised its position in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after acquiring an additional 639 shares in the last quarter. AlphaQuest LLC bought a new position in Vera Therapeutics during the fourth quarter valued at approximately $34,000. Alliancebernstein L.P. raised its position in Vera Therapeutics by 2.0% during the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock valued at $1,706,000 after acquiring an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its holdings in Vera Therapeutics by 22.3% during the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after purchasing an additional 1,130 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on VERA. The Goldman Sachs Group began coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. Guggenheim boosted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Cantor Fitzgerald reduced their target price on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $63.33.

Vera Therapeutics Trading Down 4.0%

VERA traded down $0.91 during trading on Tuesday, hitting $21.58. The company's stock had a trading volume of 475,017 shares, compared to its average volume of 777,633. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock's fifty day moving average price is $24.07 and its 200-day moving average price is $34.52. The firm has a market capitalization of $1.38 billion, a P/E ratio of -8.27 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period last year, the company posted ($0.56) earnings per share. Analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.